During the first three quarters, Adimmune accumulated net profits of NT$230 million, an improvement from losses of NT$251 million made during the same period last year, company data showed. Adimmune earlier this year won a government bid to supply 3.27 million flu vaccines to the Ministry of Health and Welfare for NT$786 million. The third quarter was the peak season for the delivery of flu vaccines, it said. The company also gained more orders for flu vaccines and flu vaccine ingredients from overseas markets, such as eastern Europe and Thailand. “It is an achievable target, as we will continue delivering flu vaccines to local governments and begin shipping flu vaccines to China, and gain more revenue from our contract manufacturing business,” it said.
